Kisqali™ (ribociclib) 200mg film coated tablet is a prescription medicine. From 1 July 2024 Kisqali™ is funded for HR HER2- advanced breast cancer, special authority criteria apply, please refer to www.pharmac.govt.nz. Normal doctor visit fees and prescription charges apply. It is important not to stop taking the medicine without your doctor’s advice. Kisqali™ has risks and benefits. For further information about Kisqali™ and/or its risks and benefits, refer to the Consumer Medicine Information at the website www.medsafe.govt.nz. Ask your doctor if Kisqali™ is right for you. Use strictly as directed. If symptoms continue, you need further information, or you have side effects see your doctor, pharmacist or healthcare professional. ™Registered Trademark. Novartis New Zealand Ltd, Auckland.

IMPORTANT: This stock card is for non-funded Kisqali™ only. If you have a Special Authority for Kisqali™, please contact our team to discuss prescription fulfillment.